Immunomic Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Immunomic Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10820
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Immunomic Therapeutics Inc (ITI) is a clinical-stage biotechnology company that develops patented lysosomal-associated membrane protein or lamp technology based nucleic acid immunotherapy platforms. The company’s vaccines utilize the body’s natural biochemistry to develop immune response including antibody production, cytokine release and critical immunological memory. Its oncology pipeline products at various stages of development include ITI-1000, ITI-1001, ITI-2000, ITI-3000, ITI-4000, ITI-5000, and ITI-6000. The company’s products also include ASP-4070 and ASP-0892 for treating allergy. The company also develops LAMP-vax technology vaccines that encode the expression of a fusion protein comprising the therapeutic antigen and the LAMP targeting protein. The company partners with academic centers and biotechnology companies to study the use of the UNITE platform in treating glioblastoma and acute myeloid leukemia. ITI is headquartered in Rockville, Maryland, the US.

Immunomic Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Immunomic Therapeutics Raises USD4.6 Million in Venture Financing 10
Immunomic Therapeutics Raises US$1 Million In Venture Financing 11
Immunomic Therapeutics Raises US$3 Million In Venture Financing 12
Immunomic Therapeutics Raises US$3 Million In Pre-Series B Financing Round 13
Immunomic Therapeutics Raises US$1.6 Million In Venture Financing 14
Immunomic Therapeutics Raises US$2.7 Million In Venture Financing 15
Immunomic Therapeutics Raises US$1.1 Million In Venture Financing 16
Immunomic Therapeutics Raises US$2 Million In Series A Financing 17
Partnerships 18
Immunomic Therapeutics Enters into Research Agreement with Duke University 18
Licensing Agreements 19
Immunomic Therapeutics Enters into Licensing Agreement with Trianni 19
Immunomic Therapeutics Enters into Licensing Agreement with Annias Immunotherapeutics 20
Astellas Pharma Enters into Licensing Agreement with Immunomic Therapeutics 21
Immunomic Therapeutics Enters into Licensing Agreement with Nature Technology 22
Equity Offering 23
Immunomic Therapeutics Raises USD7 Million in Private Placement of Series A Preferred Shares 23
Immunomic Therapeutics Inc – Key Competitors 24
Immunomic Therapeutics Inc – Key Employees 25
Immunomic Therapeutics Inc – Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Corporate Communications 27
Sep 10, 2018: Immunomic Therapeutics names Dr. Richard Ambinder to its Scientific Advisory Board 27
Dec 13, 2017: Immunomic Therapeutics Welcomes Key Thought Leader in Immuno-Oncology, Dr. Drew Pardoll, to Its Scientific Advisory Board 28
Nov 29, 2017: Immunomic Therapeutics’ Founder Appointed to Maryland Life Sciences Advisory Board 29
Jan 05, 2017: Immunomic Therapeutics’ Scientific Advisory Board Expansion 30
Product News 31
07/31/2017: Immunomic Therapeutics Welcomes New Oncology Advisor 31
Clinical Trials 32
Nov 22, 2017: Dr. Duane Mitchell Reports Findings of Study Aimed at Aggressive Brain Cancer 32
Oct 11, 2017: Immunomic Therapeutics Offers Travel Fund for Clinical Trial Patients 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Immunomic Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Immunomic Therapeutics Raises USD4.6 Million in Venture Financing 10
Immunomic Therapeutics Raises US$1 Million In Venture Financing 11
Immunomic Therapeutics Raises US$3 Million In Venture Financing 12
Immunomic Therapeutics Raises US$3 Million In Pre-Series B Financing Round 13
Immunomic Therapeutics Raises US$1.6 Million In Venture Financing 14
Immunomic Therapeutics Raises US$2.7 Million In Venture Financing 15
Immunomic Therapeutics Raises US$1.1 Million In Venture Financing 16
Immunomic Therapeutics Raises US$2 Million In Series A Financing 17
Immunomic Therapeutics Enters into Research Agreement with Duke University 18
Immunomic Therapeutics Enters into Licensing Agreement with Trianni 19
Immunomic Therapeutics Enters into Licensing Agreement with Annias Immunotherapeutics 20
Astellas Pharma Enters into Licensing Agreement with Immunomic Therapeutics 21
Immunomic Therapeutics Enters into Licensing Agreement with Nature Technology 22
Immunomic Therapeutics Raises USD7 Million in Private Placement of Series A Preferred Shares 23
Immunomic Therapeutics Inc, Key Competitors 24
Immunomic Therapeutics Inc, Key Employees 25

List of Figures
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Immunomic Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ultrapar Participacoes S.A.:企業の戦略・SWOT・財務分析
    Ultrapar Participacoes S.A. - Strategy, SWOT and Corporate Finance Report Summary Ultrapar Participacoes S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Kroton Educacional S.A. (KROT3):企業の財務・戦略的SWOT分析
    Kroton Educacional S.A. (KROT3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Gland Pharma Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Gland Pharma Ltd (Gland Pharma) is a healthcare products provider that develops and manufactures active pharmaceutical ingredients. The company’s products include injectables, pre filled syringes, vials, ampoules, infusions, ophthalmic solutions, lyophilized vials, dry powders, lyophilized p …
  • Medpace Inc (MEDP):企業の財務・戦略的SWOT分析
    Summary Medpace Inc (Medpace), a subsidiary of Medpace Holdings Inc is a contract research organization that develops research based drug and medical device. The organization provides services such as medical affairs, regulatory affairs and medical writing, clinical monitoring, clinical trial manage …
  • National Institute on Drug Abuse-製薬・医療分野:企業M&A・提携分析
    Summary National Institute on Drug Abuse (NIDA), a subsidiary of National Institutes of Health is a research institute that provides drug abuse and addiction services. The institute offers services in drugs of abuse such as bath salts, cocaine, heroin, inhalants, alcohol, club drugs, methamphetamine …
  • Kirin Holdings Co Ltd:企業のM&A・事業提携・投資動向
    Kirin Holdings Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kirin Holdings Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Yissum Research Development Company of the Hebrew University of Jerusalem Ltd-医療機器分野:企業M&A・提携分析
    Summary Yissum Research Development Company of the Hebrew University of Jerusalem Ltd (YRDC) is a technology transfer company that offers marketing the inventions and know-how generated by the University's researchers and students. The company’s products include exelon, doxil, cherry tomatoes and lo …
  • Cryogenmash:企業の戦略的SWOT分析
    Cryogenmash - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Quantum Fuel Systems LLC:電力:M&Aディール及び事業提携情報
    Summary Quantum Fuel Systems LLC (Quantum) is a provider of natural gas storage systems, integration and vehicle system technologies. The company produces advanced and lightweight compressed natural gas (CNG) storage tanks and fully integrated natural gas storage systems and supplies these tanks to …
  • Concho Resources Inc.:企業の戦略・SWOT・財務分析
    Concho Resources Inc. - Strategy, SWOT and Corporate Finance Report Summary Concho Resources Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Hyundai Steel Co:企業の戦略・SWOT・財務情報
    Hyundai Steel Co - Strategy, SWOT and Corporate Finance Report Summary Hyundai Steel Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Liberty International Holdings Inc:企業の戦略・SWOT・財務情報
    Liberty International Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Liberty International Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Molex LLC:企業のM&A・事業提携・投資動向
    Molex LLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Molex LLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Laredo Petroleum Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Laredo Petroleum Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Laredo Petroleum Inc (Laredo), formerly known as Laredo Petroleum Holdings, Inc., is an independent energy company that acquires assets, and explores for, develops and produces oil and natural g …
  • Tektronix, Inc.:企業の戦略・SWOT・財務分析
    Tektronix, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tektronix, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Camlin Fine Sciences Ltd:企業の戦略・SWOT・財務情報
    Camlin Fine Sciences Ltd - Strategy, SWOT and Corporate Finance Report Summary Camlin Fine Sciences Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • HCR ManorCare, Inc.:企業の戦略・SWOT・財務情報
    HCR ManorCare, Inc. - Strategy, SWOT and Corporate Finance Report Summary HCR ManorCare, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Bioton SA (BIO):企業の戦略的SWOT分析
    Bioton SA (BIO) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Owens & Minor, Inc.:企業の戦略・SWOT・財務情報
    Owens & Minor, Inc. - Strategy, SWOT and Corporate Finance Report Summary Owens & Minor, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • AgeneBio Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary AgeneBio Inc (AgeneBio) is a pharmaceutical company that develops therapies for psychiatric and neurological diseases. The company’s therapy is targeted to prevent neurodegeneration and preserve and restore cognitive function for unserved patients. Its lead candidate AGB101 is under phase 3 …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆